NetWorth
LeaderPortfolio
Datla
Mahima Datla
Rank #1380
INDIA•Healthcare•Vaccines

Mahima Datla

Net Worth
$3.03B
0% (24h)
Mahima Datla, the Managing Director of Biological E. Limited, is a prominent figure in the Indian healthcare industry, leading the company in vaccine production. With a Bachelor's degree in Business Administration Management from Webster University, London, Datla has been instrumental in driving Biological E.'s growth since joining in 2001, becoming Managing Director in 2013. Her net worth of $3.2 billion reflects her success in the vaccine sector. Datla has played a key role in the development and distribution of vaccines globally, including the COVID-19 vaccine Corbevax. Her career highlights include steering the company through significant expansion and navigating complex ownership challenges. She is a member of the Life Sciences Advisory Committee formed by the Government of Telangana and has served on the Gavi Alliance Board.

How to read Mahima Datla's profile

Public net-worth figures are estimates. They combine observable inputs—typically listed equity, disclosed transactions, and market prices—with editorial judgment where filings are incomplete (for example, private holdings, debt, or cross-holdings). For Mahima Datla, we anchor the narrative to Vaccines and Vaccines, then update the headline number as markets move. The chart on this page is meant to show trajectory, not a certified balance sheet.

When you see $3.03B alongside global rank #1380, interpret it as our best synthesis of widely cited ownership and price signals—not a claim about cash on hand. Estimates can diverge from other publishers because of different treatment of options, trusts, charitable vehicles, or illiquid assets. We document the general approach in methodology and welcome corrections via corrections.

Country (INDIA) and career milestones on this page are curated for reader context; they should be verified against primary sources when used for research. Editorial metadata for this profile is refreshed on a rolling basis, with deeper audits at least annually (last noted cycle: 2026).

Looking for depth? When available, the dossier and timeline sections below add long-form context beyond the headline number—prioritize those modules when evaluating claims about strategy, controversies, or philanthropic commitments.

The Full Dossier

Early Life

Mahima Datla's career in the pharmaceutical industry began after she graduated from Webster University, London, with a Bachelor's degree in Business Administration Management. She joined Biological E. Limited in 2001, a company founded by her grandfathers.

Rise to Success

Datla's career progressed steadily within Biological E. Limited. She was appointed Managing Director in 2013. Under her leadership, the company has expanded its vaccine portfolio, with a focus on global health initiatives and partnerships with international organizations like WHO and UNICEF. She has been instrumental in Biological E.’s push to create and deliver vaccines to combat diseases, most notably the COVID-19 vaccine, Corbevax.

Key Business Strategies

Datla has focused on a few key strategies, including the diversification of the company's vaccine portfolio, strategic partnerships, and investments in research and development. Biological E. Limited has also expanded its production capacity and distribution networks to reach more countries and populations. Datla has overseen Biological E.'s expansion into specialty generic injectables and branded formulations, enhancing its market presence.

Philanthropy

Datla is involved with the Sadhikaratha Foundation, and has also served on the board of the Global Health Innovative Technology fund. Biological E. Limited's mission is to improve health and survival and contribute to societies by providing equitable access to quality vaccines.

Career Timeline

2022

Ownership Dispute Resolved

Successfully resolved a long-standing ownership dispute.

2013

Managing Director of Biological E. Limited

Appointed Managing Director, leading the company's strategic direction.

2001

Joined Biological E. Limited

Began her career at Biological E. Limited.

Philanthropic Impact

HealthcareUndisclosed

Sadhikaratha Foundation

Member of the Board of Directors of the Sadhikaratha Foundation.

HealthcareUndisclosed

Global Health Innovative Technology Fund

Board Member of this fund for global healthcare access.

Key Business Ventures & Holdings

CompanyStakeValue
Biological E. Limited——

Net Worth History

In-Depth Analysis

Early Life

Mahima Datla's career in the pharmaceutical industry began after she graduated from Webster University, London, with a Bachelor's degree in Business Administration Management. She joined Biological E. Limited in 2001, a company founded by her grandfathers.

Rise to Success

Datla's career progressed steadily within Biological E. Limited. She was appointed Managing Director in 2013. Under her leadership, the company has expanded its vaccine portfolio, with a focus on global health initiatives and partnerships with international organizations like WHO and UNICEF. She has been instrumental in Biological E.’s push to create and deliver vaccines to combat diseases, most notably the COVID-19 vaccine, Corbevax.

Key Business Strategies

Datla has focused on a few key strategies, including the diversification of the company's vaccine portfolio, strategic partnerships, and investments in research and development. Biological E. Limited has also expanded its production capacity and distribution networks to reach more countries and populations. Datla has overseen Biological E.'s expansion into specialty generic injectables and branded formulations, enhancing its market presence.

Philanthropy

Datla is involved with the Sadhikaratha Foundation, and has also served on the board of the Global Health Innovative Technology fund. Biological E. Limited's mission is to improve health and survival and contribute to societies by providing equitable access to quality vaccines.

Data Sources & Methodology

Figures for Mahima Datla are synthesized from the sources below and cross-checked against our net worth methodology. Estimates may lag market moves; see corrections to report discrepancies.

You may also like

HubAll BillionairesHubGlobal RankingsHubNewsroom